First-in-class small molecule CA-170 targeting VISTA: A report on efficacy outcomes from a cohort of 12 malignant pleural mesothelioma (MPM) patients in study CA-170-101
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要